MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/acel.13818

Медицинская библиотека · Aging cell · 2023

Glucagon-like peptide-1 receptor agonists to expand the healthy lifespan: Current and future potentials.

Kreiner Frederik Flindt, von Scholten Bernt Johan, Kurtzhals Peter, Gough Stephen Charles Langford

СтатьяПеревод пока не подготовлен

Аннотация

To help ensure an expanded healthy lifespan for as many people as possible worldwide, there is a need to prevent or manage a number of prevalent chronic diseases directly and indirectly closely related to aging, including diabetes and obesity. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have proven beneficial in type 2 diabetes, are amongst the few medicines approved for weight management, and are also licensed for focused cardiovascular risk reduction. In addition, strong evidence suggests several other beneficial effects of the pleiotropic peptide hormone, including anti-inflammation. Consequently, GLP-1 RAs are now in advanced clinical development for the treatment of chronic kidney disease, broader cardiovascular risk reduction, metabolic liver disease and Alzheimer's disease. In sum, GLP-1 RAs are positioned as one of the pharmacotherapeutic options that can contribute to addressing the high unmet medical need characterising several prevalent aging-related diseases, potentially helping more people enjoy a prolonged healthy lifespan.

Для цитирования: Kreiner Frederik Flindt, von Scholten Bernt Johan, Kurtzhals Peter, Gough Stephen Charles Langford. Glucagon-like peptide-1 receptor agonists to expand the healthy lifespan: Current and future potentials.. Aging cell. 2023. DOI: 10.1111/acel.13818.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.